ORPHELIA Pharma Selects Tanner Pharma Group to Initiate Named Patient Program for KIMOZO® (temozolomide) in European Countries
Drug pricing regulator National Pharmaceutical Pricing Authority has revised prices of 128 drugs, including antibiotics and antiviral medications. The formulations for which the ceiling price has been fixed include antibiotic injections of Amoxicillin and Clavulanic acid; Vancomycin, asthma medication Salbutamol, cancer drug Trastuzumab, brain tumour treatment drug Temozolomide, painkiller Ibuprofen and paracetamol which is used to treat pain and fever.
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a collaboration agreement with licensing option with Nerviano Medical Sciences S.r.l. (NMS) for the next-generation highly selective and brain-penetrant PARP1 (poly (ADP-ribose) polymerase) inhibitor, NMS-293. NMS-293 has strong potential in combination with a wide variety of DNA-damaging agents, including systemic or targeted chemotherapy (Antibody-Drug Conjugates) or with DNA damage response inhibitors, in numerous tumor types. NMS-293 is in early clinical development for the treatment of patients with BRCA-mutated tumors as a single agent and in combination with temozolomide in recurrent glioblastoma.
Trial’s 73% twelve-month overall survival rate in newly diagnosed glioblastoma patients compares favorably to historical benchmark of 60% Results show median progression-free survival of 6.9 months...
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced that Dr. David Tran, Chief of the Division of Neuro-Oncology at the McKnight Brain Institute at the University of Florida, will present updated results from his investigator-initiated phase 2 pilot 2-THE-TOP clinical trial testing the safety and preliminary efficacy of Tumor Treating Fields (TTFields) together with pembrolizumab and temozolomide for the treatment of adult patients with newly diagnosed glioblastoma (GBM).
EpicentRx has commenced the Phase I PIRATE clinical trial of its lead small-molecule, RRx-001, in combination with irinotecan and temozolomide to treat recurrent or progressive malignant solid and central nervous system (CNS) tumours in paediatric patients.
Novocure announced that the Swiss Federal Office of Public Health (BAG) has added Optune in combination with temozolomide to the List of Remedies and Equipment (MiGeL) for the treatment of patients with newly diagnosed glioblastoma (GBM), effective April 1, 2021. The List of Remedies and Equipment defines which medical devices are covered by compulsory health insurance in Switzerland.
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ:NVCR) announced today that the Swiss Federal Office of Public Health (BAG) has added Optune in combination with temozolomide to the List of Remedies and Equipment (MiGeL) for the treatment of patients with newly diagnosed glioblastoma (GBM), effective April 1, 2021. The List of Remedies and Equipment defines which medical devices are covered by compulsory health insurance in Switzerland.
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ:NVCR) announced today that the Swiss Federal Office of Public Health (BAG) has added Optune in combination with temozolomide to the List of Remedies and Equipment (MiGeL) for the treatment of patients with newly diagnosed glioblastoma (GBM), effective April 1, 2021. The List of Remedies and Equipment defines which medical devices are covered by compulsory health insurance in Switzerland.